Helios Comes Out of Stealth, Reading 1,000+ Biomarkers to See Decades Into the Future of Your Health
BOSTON, Nov. 18, 2026
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
Helios Comes Out of Stealth, Reading 1,000+ Biomarkers to See Decades Into the Future of Your Health
PR Newswire
BOSTON, Nov. 18, 2026
Backed by Y Combinator and Formation VC, Helios combines at-home proteomics and AI to help people live longer, healthier lives than any generation before.
BOSTON, Nov. 18, 2026 /PRNewswire/ — Helios comes out of stealth today, opening the waitlist for an at-home test that measures more than 1,000 proteins from a single drop of blood to show how a person is aging and where their health is heading decades into the future. Users collect the sample themselves with a painless, needle-free device. The test launches in 2027 with the Helios AI Health Coach, which turns each person’s results into personalized steps to directly influence how they age.
“By the time you feel something is wrong, your biology may have been changing for years,” said Omar Abudayyeh, Ph.D., co-founder of Helios. “Helios gives people the world’s highest-resolution picture of their health: where they are today, where they’re headed decades from now, and the power to change it.”
Routine blood tests are designed to answer a specific question: is something already out of range? This testing only captures a slice of health: by the time a standard marker crosses a threshold, the underlying change has often been building for years. Helios answers a different question: how is your body aging, and where is it heading? Proteins carry signals from your body’s cells, tissues, and organs, revealing which systems are aging faster or slower and where risk may be building. Helios brings these signals together into one picture, and its AI coach turns that picture into concrete steps across lifestyle, nutrition, supplements, and follow-up care, grounded in published research.
The need is growing as more people are taking health into their own hands, with no objective way to see what they are doing inside the body. “Measurement only matters if it changes what you do next,” said Yousef Badran, M.D., co-founder of Helios. “For too long, we’ve treated health data as an endpoint rather than a starting point. We built Helios around a different idea: that understanding what’s happening inside the body should lead to more informed, personalized decisions about what comes next.“
Thousands of peer-reviewed papers support measuring proteomic signals in the blood. Studies have linked blood proteins to the development of more than 600 diseases, decades before diagnosis. Until now, proteomics has largely been limited to research labs. Helios is bringing blood proteomics into people’s homes and clinical practices.
“When assessing patients at the most granular level and providing elite level care, you cannot ignore proteomics,” said Daniel Kang, M.D., of AEON.
As science and technology advance, Helios will build on today’s insights with foundation models of human biology. Drawing on proteomics, medical records, and wearable data, these models will explore how different interventions could shape a person’s health over time. As people add their own data and new research emerges, Helios will use both to deliver deeper insights and more personalized, actionable guidance.
“In our quickly moving world, AI-enabled health insights should be able to match the speed that our own health changes,” said Jonathan Gootenberg, Ph.D., co-founder of Helios. “Helios embodies the idea that increasing amounts of data will lead to unparalleled control over our future health, eventually pushing disease from ‘soon’ to ‘never.'”
Omar Abudayyeh and Jonathan Gootenberg helped pioneer CRISPR diagnostics through their research at Harvard and MIT and co-founded Sherlock Biosciences, developer of the first FDA-authorized CRISPR-based test, as well as Proof Diagnostics and Tome Biosciences. Yousef Badran is a physician-scientist at Massachusetts General Hospital in Gastroenterology and Internal Medicine with experience in drug development and digital health. In their previous companies, the founders have raised more than $700 million in funding combined. Helios is backed by Y Combinator (F26), Formation VC, and a group of AI and technology founders, investors, and physicians.
Clinicians and consumers can join the waitlist at myhelios.com.
About Helios
Helios measures more than 1,000 proteins from across the body’s cells, tissues, and organs to give people the world’s highest-resolution picture of how they are aging and where their health is heading decades into the future, with an AI agent that guides them through concrete steps to change it. Backed by Y Combinator and Formation VC. Learn more at myhelios.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/helios-comes-out-of-stealth-reading-1-000-biomarkers-to-see-decades-into-the-future-of-your-health-302944057.html
SOURCE Helios Intelligence



